An observational study in Chronic Pancreatitis, Complication and Risk Factors, sponsored by Changhai Hospital. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Changhai Hospital · Observational
Among 41 studies in Pancreatitis, Chronic by Changhai Hospital — 13 open to participants now, 18 under way, none of them phase 3. Pancreatitis, Chronic · Changhai Hospital.
Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, this one is the 4th largest by planned enrollment of the 28 observational ones that give a count, is one of 2 that started in 2000, is one of 28 observational ones, reaches primary completion later than 10 of the 17 other live ones, and was the 3rd registered.
264 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
Browse Pancreatitis, Chronic studies →13 of the 41 studies in Pancreatitis, Chronic by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:
Changhai Hospital · Sites in China
Changhai Hospital · Sites in China
Changhai Hospital · Sites in China
Changhai Hospital · Sites in China
Changhai Hospital · Sites in China
By country, each count listing its studies:
Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2000.
This study's planned enrollment of 4,000 is above the median of 300 across 115 observational studies indexed under Pancreatitis, Chronic.
Median enrollment 134 across the 13 interventional studies, 657 across the 28 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Changhai Hospital is the lead sponsor of 355 studies on the registry; 137 are open to participants now.
1 of the studies in Pancreatitis, Chronic by Changhai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03324698Changhai HospitalThe Natural History of Chronic Pancreatitis | 2026-12-31 |
Among the 41 studies in Pancreatitis, Chronic by Changhai Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Chronic pancreatitis (CP) is a disease characterized by inflammation and their replacement by fibrotic tissue. The destruction of pancreatic function and structure are the main complications. This retrospective-prospective, multicenter, cohort study was conducted. This study aimed to observe the natural history of CP in China, analyse the risk factors for CP complications, and establish individual predictions.
In order to track changes consistently throughout the course of CP and facilitate the evaluation and study of CP, a dedicated database, CP Database (version number 2.1, YINMA Information Technology Inc., Shanghai, China), was established to collect clinical data of CP patients who were admitted to our centers. Data befor CP Database established were retrospectively collected according to the electronic medical record system and complemented through telephone, letter, and e-mail inquiries. Data were prospectively collected since CP Database was established. The following information was documented in detail: demographic data (age, sex, birthplace, et al), course of CP, medical history, history of other diseases, smoking and alcohol history, family history of pancreatic diseases and diabetes mellitus (DM), laboratory and imaging findings, and treatment strategy.
Chronic pancreatitis patients in China
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pancreatic cancer
Pancreatic cancer developed in chronic pancreatitis patients
Time frame: Dec 31, 2017
Diabetes mellitus
Endocrine insufficiency developed in chronic pancreatitis patients
Time frame: Dec 31, 2017
Steatorrhea
Exocrine insufficiency developed in chronic pancreatitis patients
Time frame: Dec 31, 2017
Pancreatic pseudocyst
Pancreatic pseudocyst developed in chronic pancreatitis patients
Time frame: Dec 31, 2017
Common bile duct stricture
Common bile duct stricture developed in chronic pancreatitis patients
Time frame: Dec 31, 2017
Started Jan 2000 (actual). Primary completion is estimated for Dec 2026, 323 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.